Skip to main content Skip to search Skip to main navigation

Swissmedic: Data on imports of illegal medicinal products via the internet

On 4 March 2021, Swissmedic announced the numbers on medicinal products illegally imported into Switzerland. In 2020, 6733 illegal imports were recorded. Compared to the previous year, the number has decreased only slightly.  Among the countries of origin, Singapore has replaced India, which has long been in the lead. It was followed by Western European countries such as the UK and Germany in particular.

Singapore is increasingly being used as a hub by suppliers of illegal medicinal products.

Which falsified medicinal products represent the majority?

Erectile stimulants continue to top the list, followed by other prescriptive medicinal products as well as sleeping pills and tranquilizers such as Xanax and Valium.

Swissmedic also warns against supposedly herbal products that, however, contain undeclared chemical active ingredients. They are advertised, especially in social media, as "herbal" and "natural" products for potency enhancement or for weight loss. Delivery often comes without a patient information leaflet or cardboard packaging.

A suspicion of an illegal drug should be reported to Swissmedic via the Medicrime contact form.

Successes in the fight against falsified medicinal products

In October 2020, German customs and the Bavarian Cybercrime Central Office succeeded in smashing a global network of illegally operating dealers in the "Hydra" investigation complex. Two people were arrested in the process. The international investigation lasted almost two years. The falsified preparations were assembled in a warehouse in Singapore, shipped by mail and sent by air freight.


Sources:

Swissmedic: Illegal imports of medicinal products in 2020: medicines from the internet are still in demand

Attorney General's Office Bamberg: Zoll und ZCB zerschlagen im Ermittlungskomplex „Hydra“ weltweites Netzwerk von Händlern illegaler und nicht zugelassener Arzneimittel – Zwei Haftbefehle vollstreckt (in German)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next